arrow
E

Emanuele Ammatuna

University Medical Center
H指数:30
被引数:3,715

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

TRANSFORM-1 Phase 3 study: Efficacy and safety of navitoclax plus ruxolitinib in patients with untreated myelofibrosis

TRANSFORM-1 III期研究:纳维托克司联合鲁索利替尼在初治骨髓纤维化患者中的有效性和安全性

Blood
IF23.1
2026-07-020
PRE
ΔNp73 isoform defines a TP53-mutant-like poor-risk subgroup of acute myeloid leukemia

ΔNp73异构体定义了一个TP53突变样不良风险亚组的急性髓系白血病

2026-01-080
OAAI
Beneficial effect of PTCy and a short duration of immune suppression on relapse risk in acute myeloid leukemia patients with pretransplant MRD

PTCy和短期免疫抑制对移植前微小残留病(MRD)阳性的急性髓系白血病患者复发风险的有益影响

2025-09-190
PRE
PML::RARα+ myeloid cells display metabolic alterations that can be targeted to treat resistant/relapse acute promyelocytic leukemias

PML::RARα+髓系细胞表现出可被靶向以治疗耐药/复发性急性早幼粒细胞白血病的代谢改变。

Leukemia
IF13.4
2025-09-100
OAAI
High mtDNA content identifies oxidative phosphorylation-driven acute myeloid leukemias and represents a therapeutic vulnerability

高mtDNA含量可识别氧化磷酸化驱动的急性髓性白血病,并代表治疗脆弱性

2025-07-140
OAAI
DGATI Inhibition Enhances Metformin-Induced Ferroptosis in AML By Targeting Lipid Metabolism

DGATI 抑制通过靶向脂质代谢增强二甲双胍诱导的AML中铁死亡

BLOOD
IF23.1
2024-11-051
PRE
The Oncogenic ΔNp73α Isoform Contributes to Aggressiveness in APL By Leading to ATRA Resistance through NANOG/BMP4 Axis Upregulation

癌基因ΔNp73α异构体通过上调NANOG/BMP4轴导致ATRA耐药性,从而促进APL的侵袭性。

BLOOD
IF23.1
2024-11-050
PRE
Midostaurin added to 10-day decitabine, for patients unfit for intensive chemotherapy with AML and higher risk MDS, irrespective of FLT3 mutational status, does not improve outcome
2024-10-050
OAAI
Need for ICU and outcome of critically ill patients with COVID-19 and haematological malignancies: results from the EPICOVIDEHA survey (vol 52, pg 1125, 2024)

重症新型冠状病毒肺炎和血液系统恶性肿瘤患者的ICU需求和结局: EPICOVIDEHA调查结果 (第52卷,1125页,2024页)

2024-05-210
OAAI
Decoding the historical tale: COVID-19 impact on haematological malignancy patients-EPICOVIDEHA insights from 2020 to 2022
2024-05-015
OAAI
Dexamethasone treatment for COVID-19 is related to increased mortality in hematologic malignancy patients: results from the EPICOVIDEHA registry

地塞米松治疗新型冠状病毒肺炎与血液系统恶性肿瘤患者的死亡率增加有关: EPICOVIDEHA注册表的结果

2024-04-042
OAAI
VISTA drives macrophages towards a pro-tumoral phenotype that promotes cancer cell phagocytosis yet down-regulates T cell responses

VISTA驱动巨噬细胞朝向促肿瘤表型,促进癌细胞吞噬作用,但下调T细胞反应

2024-03-293
OAAI
Need for ICU and outcome of critically ill patients with COVID-19 and haematological malignancies: results from the EPICOVIDEHA survey

重症新型冠状病毒肺炎和血液系统恶性肿瘤患者的ICU需求和结局: EPICOVIDEHA调查的结果

2024-02-224
OAAI
Survival in multiple myeloma and SARS-COV-2 infection through the COVID-19 pandemic: Results from the epicovideha registry

通过新型冠状病毒肺炎大流行,多发性骨髓瘤和SARS-COV-2感染的生存率: epicovideha注册表的结果

2023-12-049
OAAI
10-day decitabine versus 3+7 chemotherapy followed by allografting in older patients with acute myeloid leukaemia: an open-label, randomised, controlled, phase 3trial
2023-11-018
PRE